| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/13/2022 | 65.48% | Ladenburg Thalmann | → $21 | Initiates Coverage On | → Buy |
| 05/10/2022 | 65.48% | HC Wainwright & Co. | $14 → $21 | Maintains | Buy |
| 03/02/2022 | 10.32% | HC Wainwright & Co. | → $14 | Initiates Coverage On | → Buy |
Nuvectis Pharma Questions & Answers
The latest price target for Nuvectis Pharma (NASDAQ: NVCT) was reported by Ladenburg Thalmann on July 13, 2022. The analyst firm set a price target for $21.00 expecting NVCT to rise to within 12 months (a possible 65.48% upside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for Nuvectis Pharma (NASDAQ: NVCT) was provided by Ladenburg Thalmann, and Nuvectis Pharma initiated their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nuvectis Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nuvectis Pharma was filed on July 13, 2022 so you should expect the next rating to be made available sometime around July 13, 2023.
While ratings are subjective and will change, the latest Nuvectis Pharma (NVCT) rating was a initiated with a price target of $0.00 to $21.00. The current price Nuvectis Pharma (NVCT) is trading at is $12.69, which is within the analyst's predicted range.